Advances in the Discovery of Selective JAK Inhibitors
Author:
Publisher
Elsevier
Reference173 articles.
1. JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
2. Therapeutic targeting of Janus kinases
3. Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease
4. JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies
5. Selectivity and therapeutic inhibition of kinases: to be or not to be?
Cited by 80 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold;Bioorganic Chemistry;2024-07
2. Revealing innovative JAK1 and JAK3 inhibitors: a comprehensive study utilizing QSAR, 3D-Pharmacophore screening, molecular docking, molecular dynamics, and MM/GBSA analyses;Frontiers in Molecular Biosciences;2024-03-07
3. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment;International Journal of Molecular Sciences;2024-01-23
4. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors;Bioorganic Chemistry;2023-11
5. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization;Journal of Medicinal Chemistry;2023-09-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3